UCB SA said in its 22 October announcement about a near-term presentation of Phase IIa results for bepranemab that the company has regained all rights to the tau-targeting antibody from Roche Holding AG/Genentech Inc., marking the end of a four-year collaboration around the Alzheimer’s disease candidate.
UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership
Tau-Targeting Collaboration Dated Back To 2020
UCB is evaluating next steps for bepranemab, for which it will soon present Phase IIa data at CTAD, after Genentech terminated a four-year partnership to develop the tau-targeting antibody.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.